OCUL Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 17.96%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 92.41%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.82%. Given that Ocular Therapeutix, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Ocular Therapeutix, Inc. is more attractive than Bristol Myers Squibb Co..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.54% to investors and pays a quarterly dividend of $0.62 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 39.06x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Hologic, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 17.85%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Hologic, Inc.'s return on equity of 11.59%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 92.41%. On the other hand Hologic, Inc. has an analysts' consensus of $76.50 which suggests that it could grow by 2.69%. Given that Ocular Therapeutix, Inc. has higher upside potential than Hologic, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Hologic, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.745%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Hologic, Inc. quarterly revenues of $1B. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Hologic, Inc.'s net income of $187.3M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 39.06x versus 4.13x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 81.15%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 92.41%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -9.19%. Given that Ocular Therapeutix, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Krystal Biotech, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 37.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 39.06x versus 20.16x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -477.3% compared to Ocular Therapeutix, Inc.'s net margin of 34.76%. Ocular Therapeutix, Inc.'s return on equity of -83.37% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Ocular Therapeutix, Inc. has a consensus price target of $24.17, signalling upside risk potential of 92.41%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 6.27%. Given that Ocular Therapeutix, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.962, which suggesting that the stock is 3.834% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $14.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ocular Therapeutix, Inc.'s net income of -$69.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 39.06x versus 10.22x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.